Aktis Oncology financials
$19.69+1.76%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q1 '25 Sep 30 | Q4 '24 Jun 30 | Q3 '24 Mar 31 | Q2 '24 Dec 31 | Q1 '24 Sep 30 | Q4 '23 Jun 30 | Q3 '23 Mar 31 | Q2 '23 Dec 31 | Q1 '23 Sep 30 | Q4 '22 Jun 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.4M | $3.2M | $9.0M | $5.9M | $7.5M | $7.0M | $7.0M | $8.3M | $7.4M | $5.9M | $5.6M | $5.2M |
| Gross profit | $3.4M | $3.2M | $4.3M | -$635.0K | $349.0K | $681.0K | -$1.1M | -$1.7M | -$1.1M | $591.0K | -$887.0K | -$1.5M |
| Gross margin | 100.0% | 100.0% | 47.7% | −10.8% | 4.6% | 9.7% | −15.5% | −20.4% | −15.2% | 10.1% | −15.9% | −28.1% |
| Operating income | -$28.9M | -$22.7M | -$5.7M | -$50.7M | -$22.6M | -$15.0M | -$21.7M | -$17.9M | -$17.3M | -$12.9M | -$18.0M | -$17.7M |
| Net income | -$24.1M | -$18.3M | -$6.4M | -$108.8M | -$23.3M | -$15.7M | -$20.1M | -$17.8M | -$15.5M | -$11.2M | -$19.1M | -$16.2M |
| Net margin | −713.5% | −567.9% | −71.1% | −1858.3% | −310.4% | −223.9% | −287.5% | −213.2% | −211.3% | −190.2% | −343.0% | −311.8% |
| Diluted EPS | $-0.44 | $-0.38 | $-0.04 | $-0.91 | $-0.26 | $-0.21 | $-0.28 | $-0.25 | $-0.23 | $-0.19 | $-0.33 | $-0.28 |
| EBITDA | -$28.0M | -$22.1M | -$4.1M | -$4.0M | -$19.6M | -$11.7M | -$18.6M | -$14.9M | -$14.4M | -$10.2M | -$15.4M | -$15.0M |
| Operating cash flow | -$20.6M | -$24.2M | -$12.5M | -$8.1M | -$7.8M | -$11.3M | -$13.4M | -$8.7M | -$9.9M | -$11.2M | -$15.0M | -$11.9M |
| Free cash flow | -$21.8M | -$26.1M | -$12.7M | -$8.2M | -$8.1M | -$13.0M | -$17.6M | -$9.9M | -$12.1M | -$14.4M | -$19.8M | -$17.8M |
| Diluted shares | 55.3M | 48.6M | 154.4M | 119.7M | 91.3M | 73.1M | 72.3M | 71.6M | 68.2M | 57.6M | 57.2M | 54.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Sep 30 | Jun 30 | Mar 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $82.5M | $371.6M | $12.1M | $24.4M | $15.2M | $12.9M |
| Short-term investments | $434.8M | $166.9M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $48.3M | $51.9M | $43.4M | $41.7M |
| Total assets | $557.6M | $576.8M | $57.4M | $69.7M | $102.6M | $111.9M |
| Total liabilities | $72.8M | $70.7M | $122.6M | $126.8M | $60.7M | $58.1M |
| Shareholders' equity | $484.8M | $506.1M | -$65.2M | -$57.1M | $41.9M | $53.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology